IDEAYA Biosciences, Inc. (IDYA)
| Market Cap | 3.87B +76.6% |
| Revenue (ttm) | 234.13M +3,244.7% |
| Net Income | -175.02M |
| EPS | -1.96 |
| Shares Out | 96.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 714,064 |
| Open | 41.14 |
| Previous Close | 41.77 |
| Day's Range | 40.04 - 41.64 |
| 52-Week Range | 23.23 - 42.68 |
| Beta | -0.09 |
| Analysts | Strong Buy |
| Price Target | 52.15 (+30.02%) |
| Earnings Date | Aug 4, 2026 |
About IDYA
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhib... [Read more]
Financial Performance
In 2025, IDEAYA Biosciences's revenue was $218.71 million, an increase of 3024.43% compared to the previous year's $7.00 million. Losses were -$113.70 million, -58.58% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price target is $52.15, which is an increase of 30.02% from the latest price.
News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
Ideaya Biosciences enters IDE892 collaboration with Genentech
Ideaya Biosciences (IDYA) announced it has entered into a clinical collaboration with Genentech, a member of Roche (RHHBY), to evaluate the efficacy and safety of IDE892, its investigational MTA-coope...
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inh...
Ideaya Biosciences price target lowered to $42 from $45 at Citizens
Citizens lowered the firm’s price target on Ideaya Biosciences (IDYA) to $42 from $45 and keeps an Outperform rating on the shares following the company’s Q2 earnings report, citing “new…
Ideaya Biosciences price target raised to $60 from $58 at Wedbush
Wedbush raised the firm’s price target on Ideaya Biosciences (IDYA) to $60 from $58 and keeps an Outperform rating on the shares after the company reported second quarter financials and…
Ideaya Biosciences price target lowered to $59 from $63 at Truist
Truist lowered the firm’s price target on Ideaya Biosciences (IDYA) to $59 from $63 and keeps a Buy rating on the shares. Ideaya delivered continued execution in Q2, with darovasertib’s…
Ideaya Biosciences reports Q2 EPS ($1.22), consensus ($1.05)
Reports Q2 revenue $8.86M, consensus $7.45M. “This quarter marked another successful step forward in our mission to deliver new, potentially best-in-class precision therapies for people with cancer. W...
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology ...
IDEAYA Biosciences Earnings release: Q2 2026
IDEAYA Biosciences released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
IDEAYA Biosciences Quarterly report: Q2 2026
IDEAYA Biosciences has published its Q2 2026 quarterly earnings report on August 4, 2026.
IDEAYA Biosciences Slides: Corporate presentation
IDEAYA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Ideaya Biosciences initiates monotherapy expansion in IDE892 trial
Ideaya Biosciences (IDYA) announced that initiation of Part 2 monotherapy expansion has been achieved in its Phase 1/2 clinical trial evaluating IDE892, a methylthioadenosine-cooperative inhibitor of ...
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-de...
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2...
Ideaya Biosciences price target lowered to $63 from $65 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Ideaya Biosciences (IDYA) to $63 from $65 and keeps a Buy rating on the shares as part of a broader…
Ideaya Biosciences price target lowered to $48 from $53 at RBC Capital
RBC Capital lowered the firm’s price target on Ideaya Biosciences (IDYA) to $48 from $53 and keeps an Outperform rating on the shares as part of a broader research note…
Ideaya Biosciences elects CEO Yujiro Hata as chairman
Ideaya Biosciences (IDYA) announced that its board of directors has elected Yujiro Hata, chairman of the board. Hata is currently president and CEO, and a member of Ideaya’s board. Terry…
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elect...
Ideaya Biosciences enrolls first patient in IDE892 trial
Ideaya Biosciences (IDYA) announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, a methylthioadenosine-cooperative inhibitor of PRMT5, in combination with ...
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar...
IDEAYA Biosciences Slides: Corporate presentation
IDEAYA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common sto...
Ideaya Biosciences 5.56M share Spot Secondary priced at $27.00
JPMorgan, Jefferies, TD Cowen, UBS and Cantor Fitzgerald acted as joint book running managers for the offering.
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
Ideaya Biosciences $300M Spot Secondary re-offered at $27.00
JPMorgan, Jefferies, TD Cowen, UBS and Cantor Fitzgerald are acting as joint book running managers for the offering.